Adalta Ltd Asset Resilience Ratio
Adalta Ltd asset resilience ratio. Adalta Ltd (1AD) has an Asset Resilience Ratio of -3.70% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Adalta Ltd (1AD) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Adalta Ltd (2017–2024)
Asset resilience ratio of Adalta Ltd from 2017 to 2024. This chart shows how Adalta Ltd's Asset Resilience Ratio has changed over time. Read 1AD current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Adalta Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 1AD current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$-206.28K | -3.7% |
| Total Liquid Assets | AU$-206.28K | -3.70% |
Asset Resilience Insights
- Limited Liquidity: Adalta Ltd maintains only -3.70% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Adalta Ltd Industry Peers by Asset Resilience Ratio
Compare Adalta Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Adalta Ltd Asset Resilience Ratio by Year (2017–2024)
Adalta Ltd asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for Adalta Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | -3.70% | AU$-206.28K ≈ $-145.96K |
AU$5.57 Million ≈ $3.94 Million |
-52.44pp |
| 2020-06-30 | 48.74% | AU$3.37 Million ≈ $2.38 Million |
AU$6.91 Million ≈ $4.89 Million |
-10.94pp |
| 2019-06-30 | 59.68% | AU$5.56 Million ≈ $3.93 Million |
AU$9.31 Million ≈ $6.59 Million |
+7.73pp |
| 2018-06-30 | 51.95% | AU$2.31 Million ≈ $1.63 Million |
AU$4.44 Million ≈ $3.14 Million |
-24.99pp |
| 2017-06-30 | 76.94% | AU$6.22 Million ≈ $4.40 Million |
AU$8.09 Million ≈ $5.72 Million |
-- |
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more